98 results about "Mediator" patented technology

Compounds of Formula I are useful as mediators of protein kinases and have activity as cell proliferation inhibitors:where X, R1–R7 and R9 are as defined herein.

The invention relates to an electrochemical immunosensor, and in particular relates to a sandwich type electrochemical immunosensor which is constructed by taking Au-hybridized mesoporous carbon CMK-3(Au@CMK-3) and two electronic mediators, namely neutral red and thionine, as second antibody markers, a preparation method of the sandwich type electrochemical immunosensor, and application of the electrochemical immunosensor, which is prepared by the method, to simultaneous detection on markers of a cervical cancer. The electrochemical immunosensor can be used for simultaneously detecting two samples and overcoming the limitation of a single index, plays an important role in further improvement of the early confirming rate of the cervical cancer, and can be popularized to the field of simultaneous detection on tumor markers of other cancers.

Integrin-linked kinase (ILK) and Akt / protein kinase B (PKB) are important mediators of signaling in cardiomyocytes and can both prevent damage and promote healing associated with ischemic injury to the heart. Thus, the present invention provides for methods of screening for agents that increase the expression of ILK and / or Akt / PKB. Methods of treatment based on such agents are also provided.

The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

The present invention relates to a method for identifying allergenic proteins and peptides. More specifically, the present invention provides a method for identifying allergenic milk proteins and / or peptides comprising the steps of: providing at least one expression library comprising DNA or cDNA derived from the mammary gland tissue of a lactating mammal, preferably a lactating cow, expressing at least one protein or peptide encoded by said expression library, determining the binding capacity of said at least one protein or peptide to IgE of at least one serum of an individual who is sensitive to mammalian milk,preferably cow's milk, contacting the at least one protein or peptide exhibiting an IgE binding with basophil cells, eosinophil cells or mast cells and identifying the at least one protein or peptide as being allergenic when said basophil cells, eosinophil cells or mast cells release upon contact with at least one protein or peptide at least one mediator.

The present invention provides a novel device for biosensing and energy storage. The present invented device comprises an electrode having a nanopore structured and bio-communicationally active cyclodextrin attached thereto. The device has demonstrated robust analytical performances for direct single subtype breast cancer measurements without mediators, or native enzyme, and without antibodies labeling; the device is capable to store energy by direct bio-communication with the living cancer cells at real time is demonstrated. It is beneficial in the health care diagnostic applications.

The present invention relates to the mechanism of ARF-mediated cell growth suppression. ARF-BP1 is identified as a novel ubiquitin ligase, and a major component of ARF-containing nuclear complexes in human cells. The present invention discloses a novel mechanism of ARF-mediated p53 activation and that ARF-BP1 is a critical mediator of both p53-independent and p53-dependent tumor suppression functions of ARF. Inactivation of ARF-BP1 in normal cells stabilizes p53 and induces p53-dependent apoptosis. Inactivation of ARF-BP1, but not Mdm2, in p53-wildtype cells promotes cell growth inhibition in a manner reminiscent of ARF induction. ARF-BP1 directly binds and ubiquitinates p53 and inactivation of endogenous ARF-BP1 is crucial for ARF-mediated p53 stabilization in Mdm2-null cells. ARF-BP1 is advantageous over Mdm2 as a target for suppressing tumor cell growth regardless of p53 status.

The invention discloses a Bim (Bcl-2 interacting mediator of cell death) gene deletion fluorescent quantitative PCR (polymerase chain reaction) detection primer, a probe and a detection reagent kit, and belongs to the field of molecular biological detection. The Bim gene deletion fluorescent quantitative PCR detection primer and the probe comprise forward primers 5'-CAACAAACCCATCAGAACAGACAC-3', reverse primers 5'-ACAGCCTCTATGGAGAACAGTGATT-3 and fluorescent probes 5'-FAM-CAGACACTGGAACAAA-MGB-3'. The detection reagent kit comprises the Bim gene deletion fluorescent quantitative PCR detection primer, the probe, premixed liquid of PCR liquid and positive control samples A. The Bim gene deletion fluorescent quantitative PCR detection primer, the probe and the detection reagent kit have the advantages that Bim gene deletion mutation can be detected by the aid of the Bim gene deletion fluorescent quantitative PCR detection primer, the probe and the detection reagent kit, and the Bim gene deletion fluorescent quantitative PCR detection primer, the probe and the detection reagent kit are simple, convenient and feasible and are high in accuracy and sensitivity and particularly suitable for detecting clinical samples; Bim deletion mutation can be detected, and accordingly the Bim gene deletion fluorescent quantitative PCR detection primer, the probe and the detection reagent kit can bring convenience for guiding individual treatment on bodies.

The invention relates to a duplex RT-PCR method for synchronous detection of WDV (wheat dwarf virus) and WYSV (wheat yellow striate virus). Specific primers shown as SEQ ID No .1\2 for the WDV and specific primers shown as SEQ ID No .3\4 for the WYSV are adopted, RNA of a sample containing the two viruses is taken as a template, SEQ ID No .2\4 are taken as primers for reverse transcription, viruscDNA is obtained, the four primers are added to one PCR reaction system, 773bp and 332bp products are obtained respectively, and various parameters in the reaction process are optimized simultaneously. The duplex RT-PCR method established on the basis of the primers and used for the WDV and the WYSV is high in specificity and sensitivity, the two viruses in mediators can be detected and identifiedin one system synchronously, rapidly and accurately, good monitoring and early warning can be realized, and diseases are controlled before pandemic of virus diseases finally.

The present invention discloses novel therapeutic complex molecules, and in particular, peptidic or peptidomimetic molecules, comprising a first part which is competent for cell penetration and a second part which is able to reduce or abolish mast cell degranulation, in particular to reduce or abolish allergy mediators, including histamine secretion from mast cells and protein kinase activation, wherein the first part is connected to the second part via a linker or a direct bond that creates a conformational constraint by forming a bend or turn.

The instant application provides methods and related compositions pertaining to the identification of resistance to anticancer treatment in. a patient. In a particular embodiment, the invention provides biomarkers for the identification of resistance to anticancer treatment in a breast cancer patient, wherein a reduced expression of a MEDIATOR and / or SWI / SNF complex gene in the breast cancer cells of the patient indicates that the breast cancer cells in the patient may be successfully treated with a PI3K and / or mTOR inhibitor.

The invention relates to an application of neural stem cells in mediator influenced expression of protein P25 and P35, and discloses an application of neural stem cells in the preparation of P24 and / or P35 protein expression regulating agents, and an application of neural stem cells in the preparation of drugs for treating hypoxic-ischemic encephalopathy or neurodegenerative diseases. The research results show that neural stem cells (NSC) can modulate the expression change of P25 and P35 protein. The NSC can increase the P35 protein expression, reduce the P25 protein expression, and inhibit the excessive activation of Cdk5, thus protects and treats the brain damage, and has a prominent effect on diseases such as hypoxic-ischemic encephalopathy. A novel method and drug are provided for the brain damage diseases (HIE, etc.) and neurodegenerative diseases.